新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 干细胞&iPS » 嘉宾演讲摘要(中篇)——2018(第九届)细胞治疗国际研讨会

嘉宾演讲摘要(中篇)——2018(第九届)细胞治疗国际研讨会

来源:本站原创 2018-04-11 14:11


生物谷主办的“2018(第九届)细胞治疗国际研讨会”将于2018-5-17到19日在上海召开!本次会议将设立:

主会场:驶入快车道的细胞治疗

分会场一:细胞治疗学术专场

分会场二:细胞治疗临床研究专场

分会场三:细胞治疗产业论坛

以下是嘉宾的演讲摘要:


 
刘东方 Assistant Professor Houston Methodist Research Institute

演讲题目:快速有效预测CAR-T/NK疗效及副作用

演讲摘要:准确迅速地预测CAR T/NK细胞治疗的临床效能及其毒副作用是当今免疫细胞治疗中未解决的关键问题之一。目前,没有任何一个单一参数可以精准有效地预测CAR T/NK的临床疗效及其可能存在的毒副作用。随着免疫细胞治疗的高速发展,我们可以推测临床医生在选择不同药企相似的CAR T/NK细胞产品时将面临困境。 医疗市场缺乏高通量并排评估不同药企相似的CAR T/NK细胞产品对同一适应症病人的临床效能及其毒副作用。 该研究中,我们通过高通量,定量检测CAR T/NK免疫突触的质量来预测其临床效能和毒副作用。该技术,可能为免疫细胞的个体化,精准治疗引入新的临床检测指标及新的预测工具。
 
 

李光申 講座教授/副總院長 陽明大學臨床醫學研究所/台北市立聯合醫院

演讲题目: Research and application of mesenchymal stem cells: My 20-Year Journey

演讲摘要:Mesenchymal stem cells (MSCs) were first defined as a group of cells which were of self-renewal ability, were able to be culture-expanded for a prolonged period of time, and are able to differentiate into various lineages of connective progenies originated from embryonic mesoderm including bone, cartilage and adipose tissues. These cells were first isolated from bone marrow; subsequently, MSCs isolated from other sources such as liposuction fat, synovial tissues and trabecular bone have been reported by other investigators. Recently, it was reported that certain population of stem cells in human bone marrow, although low in frequency, were able to differentiate into cells and tissues originated from not only mesoderm, but also ectoderm.          
 
In our laboratory, we have successfully isolated and culture-expanded MSCs from human bone marrow and umbilical cord blood using negative immuno-selection and limiting dilution methods. Surface phenotype of these cells was performed using flow cytometry and surface marker phenotype was characteristic of MSCs. These MSCs were able to differentiate into progenies originated from all three germ layers including osteoblasts, chondrocytes, adipocytes, neuroglial cells and hepatocytes. In vitro functionality of these differentiated progenies was also demonstrated. Particularly, MSC-differentiated hepatocytes have been shown to be able to secrete urea and uptake of low density lipoproteins is also noted in these MSC-differentiated hepatocytes.
 
There are various applications of MSCs in biomedical research both in vitro and in vivo. The in vitro model of MSC culture can serve as an excellent model to study the control of differentiation as well as the cell fate in each lineage. Novel genes and proteins that control differentiation can also be explored in this model. Besides, it can also be used for screening of new drugs and compounds. Most important of all, MSCs are indispensable in the study of cell therapy, tissue engineering and regenerative medicine.
 
Over the years, we have published more than one hundred peer-reviewed research articles to report our findings regarding the molecular mechanisms that govern the fate choice and differentiation, as well as the plasticity andapplications of MSCs. In particular, our efforts made to elucidate how MSCs sense and respond to biophysical and mechanical stimuli have substantially contributed to the understanding of mechanobiology in MSCs.
 
In summary, it is foreseeable that in the near future, MSCs will revolutionize the treatment of a variety of diseases. Therefore, more efforts should be made to further elucidate the basic science of MSCs to accelerate their clinical translation from bench to bedside.
 
 

李宗海 研究员 上海市肿瘤研究所

演讲题目:针对实体瘤微环境的下一代CAR-T的研究与开发

演讲摘要:实体瘤恶劣微环境是严重影响CAR-T细胞免疫治疗存活及发挥功能的重要原因,因此如何由针对性第开发出一些高效能够克服这些微环境的技术,甚至把这些不利因素变成有利因素,无疑是下一代CAR-T开发的重点,我将介绍一下国内外特别是我们团队发展的一些CAR-T新技术。

 

Li Zhou VP of Cell Engineering   TxCell France

演讲题目:Developing CAR Treg for Treating Autoimmune Disease

演讲摘要:The recent FDA approvals of the first two CAR T cell treatments for blood cancers (Kymriah™ and Yescarta™) mark the beginning of a new era. This is a fast progressing area. We can expect that there will be continuation of success on CAR-T in the blood cancers and solid tumors. In addition, the technology of genetically modified T cells will move beyond oncology. Due to significant unmet need in the area of autoimmune disease, the development of CAR-Treg cell therapy to treat autoimmune diseases and induction of tolerance will likely be the next wave. At TxCell, we are uniquely positioned and dedicated in developing CAR Treg for autoimmune disease and organ transplant rejection. There are three Treg populations that TxCell has been working with, CD4CD25 FoxP3 Treg, Type I induced Treg and CD8 Treg cells. Each population has its own unique strength. Currently we are developing HLA-A2 CAR-Treg with CD4CD25 FoxP3 population as the first clinical candidate for prevention of organ transplant rejection. HLA A2 appears to be an ideal target for organ transplant rejection, as HLAs are membrane-bound protein specifically expressed on the transplanted tissues, HLA A2 expression level is high, it can robustly induce CAR-Treg activity. It has high allelic frequency--about 25% transplanted organs are HLA A2 mismatched in North America. We have shown that HLA A2 CAR-Treg cells can prevent GVHD in a mouse model. Other proof of concept data will also be presented. We have developed a robust cell manufacturing process for HLA A2 CAR-Treg cells and will start the first ever clinical trial using CAR-Treg.

想要与细胞治疗领域一线大咖面对面交流,请至官网报名:
http://meeting.bioon.com/2018cell-therapies

版权声明:本文系生物谷原创编译整理,未经本网站授权不得转载和使用。如需获取授权,请点击
温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库